Abstract | Peroxisome proliferator-activated receptor γ (PPARγ) is a critical factor for adipogenesis and glucose metabolism, but accumulating evidence demonstrates the involvement of PPARγ in skeletal metabolism as well. PPARγ agonists, the thiazolidinediones, have been widely used for the treatment of type 2 diabetes mellitus owing to their effectiveness in lowering blood glucose levels. However, the use of thiazolidinediones has been associated with bone loss and fractures. Thiazolidinedione-induced alterations in the bone marrow milieu-that is, increased bone marrow adiposity with suppression of osteogenesis-could partially explain the pathogenesis of drug-induced bone loss. Furthermore, several lines of evidence place PPARγ at the center of a regulatory loop between circadian networks and metabolic output. PPARγ exhibits a circadian expression pattern that is magnified by consumption of a high-fat diet. One gene with circadian regulation in peripheral tissues, nocturnin, has been shown to enhance PPARγ activity. Importantly, mice deficient in nocturnin are protected from diet-induced obesity, exhibit impaired circadian expression of PPARγ and have increased bone mass. This Review focuses on new findings regarding the role of PPARγ in adipose tissue and skeletal metabolism and summarizes the emerging role of PPARγ as an integral part of a complex circadian regulatory system that modulates food storage, energy consumption and skeletal metabolism.
Introduction
since the identification of peroxisome proliferatoractivated receptor γ (PParγ) as a master regulator of adipo genesis, 1 new insights have emerged that demonstrate an even more criti cal role for PParγ as a central integrator of glucose metabo lism and energy homeostasis.
2-4 the thiazolidine diones, a synthetic class of compounds, bind to PParγ and have widely been used to treat type 2 diabetes mel litus. [5] [6] [7] [8] [9] Des pite improvement in glucose and lipid metabolism and vari able effects on the cardiovascular system, a growing body of evidence demon strates unexpected adverse effects of these drugs on skeletal metabolism. [10] [11] [12] [13] [14] [15] [16] [17] although the sk eleton controls mineral homeostasis, novel evidence also suggests it acts as an active modulator of glucose metabo lism. several lines of evidence, both in clinical and animal studies, imply that altered mesen chymal stem cell (msC) fate could be the principal mechanism of thiazolidine dione-induced bone loss. For example, activa tion of PParγ by thiazolidine diones suppresses several key osteogenic transcrip tion factors in both mice and humans, 18, 19 and these changes contri bute to a decrease in bone mass. in addition, thiazolidine diones can stimulate bone re sorption, further uncoupling the bone remodeling unit.
the circadian system of gene expression is now widely accepted as an important modulator of metabolism. indeed a number of adipogenic and skeletal genes possess circadian expression profiles. 20 nevertheless, how peripheral tissues sense alterations in external cues, such as nutrient availability, is still not known. the link between the external environment and cellular metabolic responses is mediated via activation of nuclear receptors; many of these factors exhibit circadian expression profiles and are critical for glucose and lipid metabolism. 21 in line with this finding, Pparg (the gene that encodes the murine Pparγ protein) exhibits a remarkable circadian expression pattern in liver and adipose tissue, and this rhythmic response is magnified by consumption of a high-fat diet. 21, 22 this review will focus on the emerging concept of PParγ as a regulator of skeletal metabolism and summarize novel findings concerning the relationship of skeletal me tabolism to central and peripheral circadi an networks.
includes those of osteogenic origin.
1,2,23,24 unsurprisingly, given its broad expression profile, PParγ has a profound effect on a wide range of metabolic circuits. in addition to its effects on lipid and glucose metabolism, PParγ is involved in inflammation and may play a part in neoplastic growth. 2 PParγ is activated by naturally occurring ligands, such as fatty acids, as well as by compounds and ligands derived from arachidonic acid. 3, 25, 26 adipogenesis consists of integrated cascades that involve several transcription factors. the initial step of adipo genesis is the lineage commitment of msCs followed by the expansion of pre adipocytes. PParγ is a critical component in adipogenesis, as indicated by the fact that loss of Pparg expression in murine embryonic fibroblasts leads to a complete absence of adipo genic capacity. 27 Haploinsufficiency of Pparg, on the other hand, increases bone mass. 28 upon ligand binding, PParγ forms a dimer with the retinoic acid receptor α and initiates transcription by binding to the promoter of its target genes, such as CD36 (which encodes platelet glycoprotein 4, also known as fatty acid translocase) and FABP4 (which encodes fatty acid-binding protein 4). multiple regulatory controls act to modulate activity of this nuclear receptor and transcriptional factor.
regulation of PPArγ activity
Transcriptional regulation a number of transcription factors are involved in the regula tion of PPARG expression and function. transcription factors of the CCaat/enhancer-binding protein (C/eBP) family, C/eBPs α, β and δ, stimulate PPARG transcription by directly binding to the promoter region. 29 Given that adipocytes share common precursor progenitor cells with osteoblasts, entrance into the adipocytic or osteoblastic lineages is thought to be mutually exclusive. the homeobox protein msX2, which stimulates osteoblastogenesis, represses adipogenesis via inhibition of C/eBPα-driven PPARG transcriptional activity. 30, 31 similarly, activation of PParγ by the thiazolidine dione rosiglitazone leads to enhanced bone marrow adi posity and suppressed osteoblasto genesis. However, under certain circumstances, msCs might conceivably enter both lineages simulta neously, resulting in high bone mass and bone marrow adipogenesis.
PPARG expression and function is also positively regulated by other transcription factors during adipogenesis, including sterol regulatory element-binding protein 1c (sreBP1c), Krueppel-like factor (KlF) 5, KlF15, Zinc finger protein 423 (ZFP423) and transcription factor Coe1 (also known as early B cell factor; eBF1). KlF2 and Gata-binding proteins 2 and 3, on the other hand, negatively regulate PPARG expression. 4, [32] [33] [34] [35] [36] Histone modification another level of regulation of PParγ's transcriptional activity is its ability to modify histones. in the absence of ligand binding, PParγ forms a protein complex with corepressors, such as nuclear receptor core pressor 1 (nCor1) and nCor2 (also known as silencing mediator of retinoic acid and thyroid hormone receptor; smrt), as well as histone deacetylases (HDaCs), as a result of which PParγ is transcriptionally silent. 37 upon ligand binding, HDaCs are dissociated from this protein complex and coactivators, such as CreB-binding protein (CBP) and histone acetyltransferases, are recruited.
Histone methylation also plays a critical part in the regulation of PParγ activation as evidenced by the fact that noncanonical wnt pathways, activated by wnt5a, suppress PParγ transcriptional activation via the histone-lysine n-methyltransferase setDB1. 38 
Post-translational modification
Post-translational modifications of PParγ may also be important to regulate its activity. Phosphorylation of PParγ2 at ser112 by secretory factors, such as epidermal growth factor (eGF) and platelet-derived growth factor (PDGF), results in impaired PParγ2 transcriptional activity. [39] [40] [41] in addition to phosphorylation, sumoylation and ubiquitination confer a different level of post-transcriptional PParγ regulation. [42] [43] [44] Thiazolidinediones effects on adipose tissue thiazolidine diones, a synthetic class of compounds, also activate PParγ and have been shown to improve insulin resistance in rodents and humans.
5-9 the mechanisms by which thiazolidine diones improve insulin resistance involve multiple pathways. thiazolidinediones increase PPARG expression and stimulate PParγ transcriptional activity in adipose tissue, resulting in the upregulation of genes involved in lipid metabolism, such as CD36, FABP4 and LPL (which encodes lipoprotein lipase). 3 these changes in gene expression enhance the incorporation of free fatty acids (FFas) into adipose tissue, which eventually decreases serum FFa levels and improves lipid deposition in liver and skeletal muscle. lipid redistribu tion from visceral to subcutaneous adipose tissue depots by thiazolidinediones also has an important role for the improvement of insulin sensitivity, because visceral adipose tissue, rather than sub cutaneous adipose tissue, is associated with the development of metabolic complications related to obesity. 45, 46 in addition, PParγ activation by thiazolidine diones leads to an increase in the number of small adipocytes as a result of apoptosis of hypertrophic adipocytes. 47 as small adipocytes are associ ated with improved insulin sensitivity-in part through increased expression of insulin-sensitizing secretory factors such as adiponectin and decreased expression of genes that cause insulin resistance such as tumor necrosis factor reviews (TNF)-one underlying mechanism of thiazolidine dione action could be altering adipose tissue composition.
effects on liver and skeletal muscle PPARG is also expressed in the liver and in skeletal muscle, albeit at lower levels than in adipose tissue. treatment with thiazolidine diones might stimulate lipid accumulation in the liver, as suggested by findings that activation of hepatic Pparγ enhances the accumulation of lipids and that deletion of Pparg expression in liver reduced lipid accumulation in a diabetic mouse model. 48 But the lipid and glucose-lowering effect of thiazolidine diones through modulation of adipose tissue metabolism potentially predominates over the local effects of thiazolidinediones in liver. in other words, thiazolidine diones increase the production of adiponectin in adipo cytes, and as a result of reduced adipocyte size, lipid oxidation in the liver may be enhanced. the role of PParγ in skeletal muscle, however, is still contro versial. 49, 50 nevertheless, the net effect of thiazolidine diones is to improve lipid and glucose metabol ic status.
Bone marrow adiposity and the skeleton effects of metabolic disruption on bone the skeleton is a dynamic organ in which bone formation and resorption are tightly coupled. Bone formation occurs as a result of activated osteoblasts, whereas bone resorption occurs following osteoclast differentiation. Bone is the largest reservoir of minerals such as calcium and phosphate in the body and plays a pivotal part in mineral homeostasis. 51 Disruption of bone remodeling is often observed in physiological and pathological conditions. For example, in states of calorie deprivation, the skeleton maintains mineral homeostasis by favoring bone resorption over bone formation. 51 in addition to this canonical function, bone also possesses an important role in glucose homeostasis. Growing evidence suggests that the skeleton is a target of the adipose-tissue-derived, secretory factor leptin, via a hypothalamic-sympathetic nervous system relay. this endocrine regulation may occur through the secretion of undercarboxylated osteocalcin, 52 ,53 which regu lates glucose metabolism by acting on adipose tissue and pancreatic β cells. insulin signaling in osteoblasts has been implicated in osteocalcinmediated regulation of glucose metabolism. 54 ,55 these lines of evidence highlight the clinical observations that bone is adversely affected by metabolic disruptions. For example, in patients with type 1 diabetes mellitus, fracture rates are high, and fractures heal poorly. similarly, patients with obesity and type 2 diabetes mellitus are at a greater risk of fractures than the general population-both as a result of the disease and treatment with thiazolidine diones-despite their obesity, which can enhance bone mass owing to the increased gravitational load on the skeleton. thus, impaired glucose utilization can profoundly affect the skeleton.
PPArγ activation and bone loss use of thiazolidine diones increases fracture risk in postmenopausal women, 10-14,16,17,56 because these drugs induce an im balance between bone formation and resorption, as shown in one short-term, randomized, placebocontrolled trial. 11 in this study, rosiglitazone reduced hip bone mass, and this phenomenon was accompanied by a decrease in serum osteocalcin levels. 11 Habib et al. 57 reported that treatment of patients with type 2 diabetes mellitus with thiazolidine diones increased the risk of fracture in women aged >65 years. as PPARG is expressed in msCs and is an important regulator of msC specification toward adipo genesis versus osteogenesis, activation of PParγ by thiazolidine diones could alter the fate of msCs through the suppression of osteogenic transcription factors, such as homeobox protein Dlx5, runt-related transcription factor 2 (runx2) and osterix ( Figure 1) . 18, 58 in support of this tenet, haploinsufficiency of Pparg is associated with increased bone mass and reduced bone marrow adiposity, as well as increased osteoblast number and bone forma tion rates in mice. 28 in addition, Pparγ activation in mice has been shown to enhance bone resorption in vivo, in part through recruitment of the Pparγ coactivators Pgc1β and estrogen-related receptor 1 (err1).
59-62 the effect of thiazolidine diones on osteoclastogenesis could also be mediated by the increased expression of Rankl (which encodes receptor activator of nuclear factor κB ligand) in an age-dependent manner; 63 however, the exact role of PParγ in osteoclasto genesis needs further clarification. 64, 65 PPArγ activation and bone marrow adiposity aside from bone loss, activation of Pparγ is associated with increased bone marrow adiposity in rodent models, although the effect of PParγ agonists on increased bone marrow adiposity is strain-specific and drug-specific. 66 Bone marrow adipogenesis has gained increasing attention among researchers, because of its possible role as a contributor to physiologic and pathogenic conditions. Bone marrow adipocytes have long been considered inert and were thought to result from a default pathway of msC differentiation. in addition, bone marrow adipo cytes are found in abundance in states such as aplastic anemia, which suggests that adipogenesis in hibits hematopoiesis. 67 the process of bone marrow adipogenesis is probably governed by the same transcriptional cascades observed in white adipocyte differentiation, and, hence, PParγ is certain to play a pivotal part. streptozotocin-induced diabetic mice (a model of type 1 diabetes mellitus) exhibit increased bone marrow adiposity, which can be in hibited by treatment with the PParγ inhibitor bisphenol a di glycidyl ether (BaDGe). 68 Correspondingly, BaDGe also suppresses the bone marrow adipogenesis that occurs following irradiation in mice. 67 interestingly, gene expression profiling analysis revealed the existence of genes involved in thermogenesis and lipid metabolism in bone marrow adipocytes, suggesting that marrow adipocytes could be metabolically active (C. J. rosen, unpublished work). with aging, bone marrow adi posity increases in as sociation with bone loss and enhanced Pparg expression.
to date, no studies have analyzed the effect of thiazolidine diones on bone marrow adiposity in humans, but studies in mouse models have provided insights regarding their role in the development of bone marrow adi posity. 66 rosiglitazone-induced bone loss in C57Bl/6J mice is associated with increased infiltration of the bone marrow with large adipo cytes, an effect that is more pronounced in older, female mice. 66 Histomorphometric analy sis reveals suppressed bone formation and increased bone resorption, consistent with a profound imbalance in bone remodeling. Given the widely accepted tenet that adipose tissue produces a number of secretory factors that affect a wide range of meta bolic processes, it comes as no surprise that bone marrow adipocytes, especially under pathogenic conditions such as aging and treatment with thiazolidine diones, also produce secretory factors which function in the bone marrow milieu. these factors may then act in a paracrine manner to impair osteoblast differen tiation and/or function. Further investigations are, however, needed to support this hypothesis, as some evidence suggests that mice which lack bone marrow adipo cytes have normal bone mass. 69 Physiological versus pathogenic conditions Bone marrow adipocyte infiltration is often associated with bone loss, but evidence also exists of a positive correlation between bone marrow adiposity and bone mass in humans and animal models. For example, the C3H/HeJ mouse strain exhibits higher bone mass and increased bone marrow adiposity compared with the C57Bl/6J mouse strain. 70 in humans, marrow adiposity robustly increases during puberty when skeletal acquisition is maximized. 71 these lines of evidence suggest that in physiological situations bone marrow adipocytes have a distinctly different role from that in pathogenic conditions. adipocytes may be an important component of the bone marrow niche and establish a favorable skeletal microenvironment for osteoblast differentiation by functioning as a source of secretory factors and a depot for energy utilization. the role of adipocytes in hematopoiesis needs further delineation. 72 However, the process of adipo genesis that occurs in bone marrow after transplantation or injury may serve not as a true antagonist of hematopoiesis but rather as a 'place-holder' , to maintain hematopoietic progenitors in a stem cell state awaiting signals that trigger their differentiation.
Circadian regulation of PPARG
several lines of evidence demonstrate the tight connection between circadian networks and metabolic outputs, thereby placing PParγ at the center of another regulatory system. [73] [74] [75] [76] [77] For example, night-shift workers who have disrupted circadian cycles show a higher incidence of the metabolic syndrome and cardiovascular complications. 78 mutations in circadian genes are associated with sleep disorders, which can also affect metabolic status and body composition. 79 in addition, use of drugs such as glucocorticoids and second-generation antipsychotics has been shown to disrupt endogenous circadian rhythms and result in the development of metabolic phenotypes, including insulin resistance, both in humans and mice. [75] [76] [77] 80 components of the circadian clock Central components the circadian clock network is composed of central and peripheral components. the master pacemaker is located in the suprachiasmatic nucleus in the hypothalamus 81 and governs peripheral circadian rhythm by processing retinal, hormonal, nutritional and neuronal signals.
20 the 24-h rhythm is integrated by a series of transcriptional, translational and post-translational mechanisms that involve a number of genes, including CLOCK (which encodes circa dian locomoter output cycles protein kaput), BMAL1 (which encodes brain and muscle arnt-like 1; also known as arntl), PER (which encodes period circadian protein) and CRY (which encodes cryptochrome). 82 CloCK hetero dimerizes with Bmal1 and activates transcription of PER and CRY through enhancer elements called e-boxes. a complex consisting of Per and CrY in turn suppresses CloCK and Bmal1 transcriptional activity, thus forming a 24-h feedback loop. Besides this core feedback loop, growing evidence suggests the existence of other factors involved in 24-h rhythms. For example, the nuclear receptors rev-erBα and rorα, whose transcription is driven by the CloCK and Bmal1 complex, are shown to suppress and enhance BMAL1 transcription, respectively. 83 as most physiological activities, such as feeding and energy expenditure, are regulated in a circadian manner, disruptions of this feedback loop affect the rhythmicity of these activities, which results in alterations in metabolic status. indeed, mutant mice that lack the Clock gene exhibit an impaired diurnal feeding rhythm and hyperphagia associated with metabolic derangements. 80 reviews Peripheral components the central clock network has a well-established, critical role in the regulation of metabolism; however, a growing body of evidence suggests that peripheral tissues also possess cell-autonomous regulatory systems that are independent of the central clock, but use the same machinery of genes in the same temporal pattern. Given that entrainment to external stimuli, such as food intake, needs to be accomplished in a way that peripheral tissues change their metabolic status in a timely manner, it comes as no surprise that these tissues can function independently (but in coordination with the central clock) through alterations in gene expression. Kornmann et al. 84 analyzed gene expression in transgenic mice with a conditionally active liver clock, in which rev-erbα repressed Bmal1 transcription under the control of tetracycline. the researchers identified 351 circadian-regulated genes in the liver of these transgenic mice, including genes involved in energy and glucose metabolism. the majority of these genes changed their rhythmic expression pattern when the liver oscillator was suppressed. on the other hand, 31 genes were still rhythmic in the absence of liver oscillation. these data imply that the liver oscillator is critical for the regulation of rhythmic gene expression.
linking metabolism and the circadian clock accumulating evidence clearly demonstrates a link between circadian clock genes and metabolic output in peripheral tissues. the mechanisms by which metabolic status is controlled by the circadian clock is, however, still largely unknown. nuclear receptors could have an important role in this regulation, because metabolic physiology, such as lipid and glucose disposal, as well as adipogenesis, requires activation of these factors. 85 importantly, many nuclear receptors exhibit rhythmic circadian patterns of expression in peripheral tissues. 21 For example, PParγ shows circadian expression in liver and adipose tissue. interestingly, Pparg oscillation in the liver is magnified by a high-fat diet. in addition, the thiazolidine dione pioglitazone has been shown to shift the circadian rhythm of blood pressure in patients with type 2 diabetes mellitus. 86 thus, PParγ, activated by thiazolidine diones, could conceivably affect the circadian rhythm, which might result in the alteration of metabolic status.
PGC1α
the inducible PParγ coactivator 1α (PGC1α) also ex hibits a circadian expression pattern. the Pgc1α-deficient mouse strain shows disrupted locomotor acti vity, diurnal oscillation of body temperature and energy metabolism. 87 Clock, Bmal1 and Per1 gene expression, as well as metabolic factors, such as phos phoenolpyruvate carboxykinase (Pck) and pyruvate dehydrogenase kinase 4 (Pdk4), are also altered by the lack of Pgc1α in the liver of these mice. 87 restricted feeding reversed the circadian expression pattern of Pgc1α, Bmal1, Cry1 and Cry2 in livers of wild-type mice, but this adaptation of gene expression was disrupted in the liver of the Pgc1α-deficient mouse. 87 thus, PGC1α may be one factor linking external stimuli and cellular outputs by modulating clock genes and the transcriptional activity of nuclear receptors.
Nocturnin
Green et al. 88 previously identified a circadian-regulated gene, nocturnin (Noc), in the retina of Xenopus laevis. in mice, Noc expression peaks at the start of the dark cycle in most tissues, including liver, kidney, skeleton and spleen. 89 noc belongs to a family of proteins that includes transcription factors, deadenylases and phosphatases. [90] [91] [92] it shares sequence similarities with the inducible yeast gene Ccr4p, which functions as a transcription factor and deadenylase. noc, however, lacks the transactivation domain found in Ccr4p. 88, [92] [93] Noc is also an inducible gene and its expression is upregulated in response to fetal calf serum and insulin in the niH3t3 and 3t3-l1 cell lines. 90, 94 Hepatic noc expression is also enhanced with aging. 95 importantly, Pparγ activation in bone marrow stromal cells induced Noc gene expression nearly 30-fold. 18 ,96 the offspring of mice fed a western-like highfat diet develop obesity over four generations, and Noc is one of the most upregulated genes in the stromal vascular fractions of adipose tissue from these mice. 97 thus, noc seems to be important in lipid homeostasis.
to investigate the metabolic role of noc, detailed ana lyses of mice with a knockout of the Noc gene were performed. 22 Noc-deficient mice showed normal phaseshifts to light pulses and unaltered food intake, but were protected from fatty liver and obesity induced by a highfat diet. 22 interestingly, the circadian expression pattern of Pparg in the liver disappeared in Noc-deficient mice fed a high-fat diet and was accompanied by a decrease in expression of genes involved in lipid metabolism, including Srebp1a, Scd1 (which encodes stearoyl-Coa desaturase 1) and Fabpl (which encodes liver fatty acidbinding protein). these data imply that noc regulates lipid metabolism by modulating Pparγ activity. to support this notion, noc has been shown to stimulate Figure 2 | Nocturnin regulates PPARγ's circadian profile and activity. The circadianregulated gene, nocturnin, which is induced by external cues such as aging, high-fat diet and insulin, is exclusively expressed in the cytoplasm and nuclear membrane. Nocturnin binds to PPARγ and enhances the transcriptional activity of PPARγ. This effect is in part exerted by its activity to stimulate the nuclear translocation of PPARγ. Enhanced activity of PPARγ by nocturnin may result in increased bone marrow adiposity and bone loss. white and black bars represent light and dark cycle, respectively. Abbreviations: MSCs, mesenchymal stem cells; Noc, nocturnin; PPARγ, peroxisome proliferator-activated receptor γ; RXRα, retinoid X receptor α.
reviews adipogenesis of 3t3-l1 cells by increasing expression of C/EBPα, Pparg2, aP2 and Lpl. in addition, noc was found to bind to Pparγ directly and enhance its transcriptional activity (Figure 2 ). 94 surprisingly, noc protein expression is exclusively limited to the cytoplasm and nuclear membrane, ruling out the possibility of noc as a coactivator of Pparγ; however, detailed analyses using cell fractionation and immuno fluorescence revealed that noc stimulates the nuclear translocation of Pparγ. interestingly, this effect is independent of its deadenylase activity. 94 Consistent with these findings, Noc-deficient mice exhibit low bone marrow adiposity and high bone mass, supporting the function of noc as a positive modulator of Pparγ acti vity. 94 as Noc expression is induced by exposure to fetal calf serum and insulin, noc may be a key factor linking external stimuli and metabolic output by activating Pparγ.
Conclusions
advances in PParγ biology have provided new insights into an emerging field of metabolism and its relationship to skeletal homeostasis via circadian-regulated factors. as is increasingly recognized, PParγ activation entrains multiple pathways, some of which may be benefi cial, whereas others may be harmful. nevertheless, thiazolidine diones are widely prescribed for the treatment of type 2 diabetes mellitus. new insights into the multifunctional nature of PParγ may allow for the development of novel agents that specifically target adipocyte pro genitors, with minimal or no adverse effects to the skeleton. Concomitantly, PParγ antagonists specific to the osteoblastic lineage could be an attractive candidate for the treatment of osteoporosis. Further translational studies are needed to bridge results from bench studies into the clinical arena. However, care ful study of the highly integrated connection between circa dian rhythms and metabolic output should provide a head start on drug development for both obesity and osteoporosis.
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